Literature DB >> 25074640

Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV.

Eugene A Kiyatkin1, Albert H Kim1, Ken T Wakabayashi1, Michael H Baumann1, Yavin Shaham1.   

Abstract

3,4-Methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone (MDPV) are new drugs of abuse that have gained worldwide popularity. These drugs are structurally similar to 3,4-methylenedioxymethamphetamine (MDMA) and share many of its physiological and behavioral effects in humans, including the development of hyperthermia during acute intoxication. Here, we examined the effects of methylone (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain temperature homeostasis in rats maintained in a standard laboratory environment (single-housed in a quiet rest at 22 °C) and under conditions that model human drug use (social interaction and 29 °C ambient temperature). By simultaneously monitoring temperatures in the nucleus accumbens, temporal muscle, and facial skin, we assessed the effects of methylone and MDPV on intra-brain heat production and cutaneous vascular tone, two critical factors that control brain temperature responses. Both methylone and MDPV dose-dependently increased brain temperature, but even at high doses that induced robust locomotor activation, hyperthermia was modest in magnitude (up to ∼2 °C). Both drugs also induced dose-dependent peripheral vasoconstriction, which appears to be a primary mechanism determining the brain hyperthermic responses. In contrast to the powerful potentiation of MDMA-induced hyperthermia by social interaction and warm ambient temperature, such potentiation was absent for methylone and minimal for MDPV. Taken together, despite structural similarities to MDMA, exposure to methylone or MDPV under conditions commonly associated with human drug use does not lead to profound elevations in brain temperature and sustained vasoconstriction, two critical factors associated with MDMA toxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25074640      PMCID: PMC4443958          DOI: 10.1038/npp.2014.191

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  28 in total

Review 1.  The hidden side of drug action: brain temperature changes induced by neuroactive drugs.

Authors:  Eugene A Kiyatkin
Journal:  Psychopharmacology (Berl)       Date:  2012-12-29       Impact factor: 4.530

Review 2.  From motivation to action: functional interface between the limbic system and the motor system.

Authors:  G J Mogenson; D L Jones; C Y Yim
Journal:  Prog Neurobiol       Date:  1980       Impact factor: 11.685

Review 3.  Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone.

Authors:  Edward A Ross; Gary M Reisfield; Mary C Watson; Chris W Chronister; Bruce A Goldberger
Journal:  Am J Med       Date:  2012-06-09       Impact factor: 4.965

4.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

5.  Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions.

Authors:  P Leon Brown; Eugene A Kiyatkin
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

6.  Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Authors:  Michael H Baumann; John S Partilla; Kurt R Lehner; Eric B Thorndike; Alexander F Hoffman; Marion Holy; Richard B Rothman; Steven R Goldberg; Carl R Lupica; Harald H Sitte; Simon D Brandt; Srihari R Tella; Nicholas V Cozzi; Charles W Schindler
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

7.  In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Authors:  William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

8.  Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use.

Authors:  Eugene A Kiyatkin; Albert H Kim; Ken T Wakabayashi; Michael H Baumann; Yavin Shaham
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

Review 9.  Psychoactive "bath salts": not so soothing.

Authors:  Michael H Baumann; John S Partilla; Kurt R Lehner
Journal:  Eur J Pharmacol       Date:  2012-11-23       Impact factor: 4.432

10.  Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter.

Authors:  Krasnodara N Cameron; Renata Kolanos; Ernesto Solis; Richard A Glennon; Louis J De Felice
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

View more
  19 in total

1.  Reinforcing and neurochemical effects of the "bath salts" constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats.

Authors:  Charles W Schindler; Eric B Thorndike; Steven R Goldberg; Kurt R Lehner; Nicholas V Cozzi; Simon D Brandt; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2015-08-29       Impact factor: 4.530

2.  Conditioned taste avoidance, conditioned place preference and hyperthermia induced by the second generation 'bath salt' α-pyrrolidinopentiophenone (α-PVP).

Authors:  Katharine H Nelson; Briana J Hempel; Matthew M Clasen; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2017-04-17       Impact factor: 3.533

3.  The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity.

Authors:  Luis M Colon-Perez; Kelvin Tran; Khalil Thompson; Michael C Pace; Kenneth Blum; Bruce A Goldberger; Mark S Gold; Adriaan W Bruijnzeel; Barry Setlow; Marcelo Febo
Journal:  Neuropsychopharmacology       Date:  2016-03-21       Impact factor: 7.853

4.  Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells.

Authors:  Hector Rosas-Hernandez; Elvis Cuevas; Susan M Lantz; Kenner C Rice; Brenda M Gannon; William E Fantegrossi; Carmen Gonzalez; Merle G Paule; Syed F Ali
Journal:  Neurosci Lett       Date:  2016-06-16       Impact factor: 3.046

Review 5.  Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP).

Authors:  Richard A Glennon; Richard Young
Journal:  Brain Res Bull       Date:  2016-04-29       Impact factor: 4.077

6.  MDMA, Methylone, and MDPV: Drug-Induced Brain Hyperthermia and Its Modulation by Activity State and Environment.

Authors:  Eugene A Kiyatkin; Suelynn E Ren
Journal:  Curr Top Behav Neurosci       Date:  2017

7.  Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).

Authors:  Kaveish Sewalia; Lucas R Watterson; Alyssa Hryciw; Anna Belloc; J Bryce Ortiz; M Foster Olive
Journal:  Neuropharmacology       Date:  2017-11-26       Impact factor: 5.250

Review 8.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

Review 9.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

10.  Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats.

Authors:  Joshua S Elmore; Ora Dillon-Carter; John S Partilla; Kayla N Ellefsen; Marta Concheiro; Masaki Suzuki; Kenner C Rice; Marilyn A Huestis; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2016-09-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.